CaRi-Heart for Drug Clinical Trials

About Caristo Diagnostics

Caristo Diagnostics is an emerging leader in AI-driven cardiac diagnostics, leveraging over two decades of research to commercialize its CaRi-Heart® platform. The technology extracts novel biomarkers, like the FAI-Score™ for perivascular inflammation, from standard Coronary Computed Tomography Angiography (CCTA) images, providing clinicians with enhanced risk assessment tools beyond traditional measures. With applications in preventive screening, clinical diagnosis, and drug development support, Caristo is positioning itself at the intersection of cardiovascular medicine and artificial intelligence. The company is privately held, has garnered significant scientific recognition, and is focused on expanding clinical adoption through partnerships with imaging centers.

Therapeutic Areas